Cosmo Pharmaceuticals SpA, an Italian company specialising in developing and manufacturing treatments for gastro-intestinal diseases, has licensed two of its advanced drug candidates to Santarus Inc. of the United States in a deal that will leave Cosmo with a 10.5% holding in Santarus and with the possibility of acquiring more shares.
